Aspire expands oncology portfolio with prostate cancer hormone therapy

One man dies from prostate cancer every 45 minutes in the UK 

Aspire Pharma Limited has solidified its position as a leading specialty generics enterprise by adding leuprorelin acetate as a branded generic to its oncology portfolio.

Leuprorelin acetate is hormone therapy recommended for patients with high-risk localised, locally advanced, and metastatic prostate cancer, serving as an alternative to surgical castration for locally advanced cases.

Used as an alternative to surgical castration for locally advanced prostate cancer, a pre-filled syringe containing 11.25mg of leuprorelin acetate (equivalent to 10.72 mg leuprorelin) is injected subcutaneously into the abdomen.

The British pharmaceutical company noted that one of its primary objectives is to seek “new investment opportunities” that brings products and companies into its portfolio, aligning closely with Aspire values and therapeutic focus areas.

Prostate cancer is the most common cancer among men in the UK, with an average of over 52,000 men receiving a diagnosis of prostate cancer annually, as per Prostate Cancer UK.

One man dies from prostate cancer every 45 minutes, equating to more than 12,000 men every year.

Prostate cancer mainly affects men over 50, and the risk increases with age.

Prostate Cancer UK in collaboration with the UK government is set to launch a massive screening trial this year.

Backed by £16 million of government funding, the £42 million TRANSFORM trial is set to become the largest prostate cancer diagnosis trial in two decades, involving hundreds of thousands of men. Recruitment for the trial is expected to commence in Autumn 2024.

The trial will use innovative screening methods like an MRI scan to detect prostate cancer.

Commenting on this collaboration, Health Secretary Victoria Atkins previously said that thousands of men’s lives could be saved each year if prostate cancer is detected early with advanced screening methods.

By collaborating with the NHS, Aspire aims to enhance services for prostate cancer patients “bringing care closer to home, while delivering a more cost-effective prescribing option for commissioners.”